New and Emerging Treatments for Schizophrenia | Dr. Christoph Correll

2025 APA Scientific Conference

50% of survey complete.

Please click "Next" if you did not attend this session

Question Title

* The session met the stated learning objectives:

	Strongly disagree	Disagree	Somewhat disagree	Neither agree or disagree	Somewhat agree	Agree	Strongly agree
Recognize efficacy and tolerability characteristics and gaps of current postsynaptic antidopaminergic antipsychotic agents;	Recognize efficacy and tolerability characteristics and gaps of current postsynaptic antidopaminergic antipsychotic agents; Strongly disagree	Recognize efficacy and tolerability characteristics and gaps of current postsynaptic antidopaminergic antipsychotic agents; Disagree	Recognize efficacy and tolerability characteristics and gaps of current postsynaptic antidopaminergic antipsychotic agents; Somewhat disagree	Recognize efficacy and tolerability characteristics and gaps of current postsynaptic antidopaminergic antipsychotic agents; Neither agree or disagree	Recognize efficacy and tolerability characteristics and gaps of current postsynaptic antidopaminergic antipsychotic agents; Somewhat agree	Recognize efficacy and tolerability characteristics and gaps of current postsynaptic antidopaminergic antipsychotic agents; Agree	Recognize efficacy and tolerability characteristics and gaps of current postsynaptic antidopaminergic antipsychotic agents; Strongly agree
Identify mechanisms of action and efficacy signals of new and emerging molecules beyond postsynaptic dopamine blockade targeting different symptom domains in schizophrenia; and	Identify mechanisms of action and efficacy signals of new and emerging molecules beyond postsynaptic dopamine blockade targeting different symptom domains in schizophrenia; and Strongly disagree	Identify mechanisms of action and efficacy signals of new and emerging molecules beyond postsynaptic dopamine blockade targeting different symptom domains in schizophrenia; and Disagree	Identify mechanisms of action and efficacy signals of new and emerging molecules beyond postsynaptic dopamine blockade targeting different symptom domains in schizophrenia; and Somewhat disagree	Identify mechanisms of action and efficacy signals of new and emerging molecules beyond postsynaptic dopamine blockade targeting different symptom domains in schizophrenia; and Neither agree or disagree	Identify mechanisms of action and efficacy signals of new and emerging molecules beyond postsynaptic dopamine blockade targeting different symptom domains in schizophrenia; and Somewhat agree	Identify mechanisms of action and efficacy signals of new and emerging molecules beyond postsynaptic dopamine blockade targeting different symptom domains in schizophrenia; and Agree	Identify mechanisms of action and efficacy signals of new and emerging molecules beyond postsynaptic dopamine blockade targeting different symptom domains in schizophrenia; and Strongly agree
Differentiate adverse effect profiles of new and emerging treatments for schizophrenia from agents with postsynaptic dopamine modulation and from each other.	Differentiate adverse effect profiles of new and emerging treatments for schizophrenia from agents with postsynaptic dopamine modulation and from each other. Strongly disagree	Differentiate adverse effect profiles of new and emerging treatments for schizophrenia from agents with postsynaptic dopamine modulation and from each other. Disagree	Differentiate adverse effect profiles of new and emerging treatments for schizophrenia from agents with postsynaptic dopamine modulation and from each other. Somewhat disagree	Differentiate adverse effect profiles of new and emerging treatments for schizophrenia from agents with postsynaptic dopamine modulation and from each other. Neither agree or disagree	Differentiate adverse effect profiles of new and emerging treatments for schizophrenia from agents with postsynaptic dopamine modulation and from each other. Somewhat agree	Differentiate adverse effect profiles of new and emerging treatments for schizophrenia from agents with postsynaptic dopamine modulation and from each other. Agree	Differentiate adverse effect profiles of new and emerging treatments for schizophrenia from agents with postsynaptic dopamine modulation and from each other. Strongly agree

Question Title

* Please rate the following on a scale of 1 to 5
(1 - strongly disagree and 5 - strongly agree):

	Strongly disagree	Disagree	Somewhat disagree	Neither agree or disagree	Somewhat agree	Agree	Strongly agree
The session was educationally relevant.	The session was educationally relevant. Strongly disagree	The session was educationally relevant. Disagree	The session was educationally relevant. Somewhat disagree	The session was educationally relevant. Neither agree or disagree	The session was educationally relevant. Somewhat agree	The session was educationally relevant. Agree	The session was educationally relevant. Strongly agree
The presenter was educationally effective.	The presenter was educationally effective. Strongly disagree	The presenter was educationally effective. Disagree	The presenter was educationally effective. Somewhat disagree	The presenter was educationally effective. Neither agree or disagree	The presenter was educationally effective. Somewhat agree	The presenter was educationally effective. Agree	The presenter was educationally effective. Strongly agree
The session provided interactive opportunities.	The session provided interactive opportunities. Strongly disagree	The session provided interactive opportunities. Disagree	The session provided interactive opportunities. Somewhat disagree	The session provided interactive opportunities. Neither agree or disagree	The session provided interactive opportunities. Somewhat agree	The session provided interactive opportunities. Agree	The session provided interactive opportunities. Strongly agree
The session provided opportunities to identify and/or reflect on what was learned and its potential impact on my practice	The session provided opportunities to identify and/or reflect on what was learned and its potential impact on my practice Strongly disagree	The session provided opportunities to identify and/or reflect on what was learned and its potential impact on my practice Disagree	The session provided opportunities to identify and/or reflect on what was learned and its potential impact on my practice Somewhat disagree	The session provided opportunities to identify and/or reflect on what was learned and its potential impact on my practice Neither agree or disagree	The session provided opportunities to identify and/or reflect on what was learned and its potential impact on my practice Somewhat agree	The session provided opportunities to identify and/or reflect on what was learned and its potential impact on my practice Agree	The session provided opportunities to identify and/or reflect on what was learned and its potential impact on my practice Strongly agree

Comments:

Question Title

* Please rate the following on a scale of 1 to 5
(1 - strongly disagree and 5 - strongly agree):

	Strongly disagree	Disagree	Somewhat disagree	Neither agree or disagree	Somewhat agree	Agree	Strongly agree
The session and presenter did NOT have commercial or other inappropriate bias.	The session and presenter did NOT have commercial or other inappropriate bias. Strongly disagree	The session and presenter did NOT have commercial or other inappropriate bias. Disagree	The session and presenter did NOT have commercial or other inappropriate bias. Somewhat disagree	The session and presenter did NOT have commercial or other inappropriate bias. Neither agree or disagree	The session and presenter did NOT have commercial or other inappropriate bias. Somewhat agree	The session and presenter did NOT have commercial or other inappropriate bias. Agree	The session and presenter did NOT have commercial or other inappropriate bias. Strongly agree

Comments:

Question Title

* Please provide any other comments you would like to share: